GenFlow Biosciences is a biotech company that develops gene therapies for slow or reverse aging in humans and animals.
Genflow Biosciences has raised $1.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Genflow Biosciences's investors include Longevitytech.fund, Walloon, Eric Leire.
Genflow Biosciences is headquartered in London, United Kingdom.
GenFlow Biosciences is a biotech company that develops gene therapies for slow or reverse aging in humans and animals.
Genflow Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genflow Biosciences — Funding & Investors." VCBacked, March 5, 2026, https://www.vcbacked.co/company/genflow-biosciences. Accessed August 15, 2026.
VCBacked. (2026). Genflow Biosciences — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/genflow-biosciences
{{cite web |title=Genflow Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/genflow-biosciences |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated